£1M FOR RESEARCH APPEAL

We need you to help us raise £365k in 365 days so that together, we will have raised £1,000,000 for research. DONATE

Giving hope to those affected
by secondary breast cancer

Research. Support. Education.

UK Clinical Trial Registry

This registry lists all of the clinical trials that are currently actively recruiting secondary breast cancer patients in the UK.

Currently, patients and healthcare professionals have to search many different databases, such as clinicaltrials.gov, NIHR Be Part of Research or Cancer Research UK, to see what trials might be available. These databases use different search algorithms and the outcome of searches can be different and very time-consuming. This registry is intended as a “one stop shop” for UK secondary breast cancer clinical trials.

Clinical Trials for Secondary (Metastatic) Breast Cancer

The registry is divided into different categories based on the medical classification of secondary breast cancer. You can select a category to see a list of available trials and click on the study links to find the eligibility criteria. If you are unsure of your subtype, please speak to your clinical team. You can read more about the subtypes and receptors for breast cancer here

Next steps

If you are interested in trials, it is important to have a conversation with your clinical team and people around you who can support you. At Make 2nds Count, we offer an impartial and confidential Patient Trials Advocate (PTA) service for those interested in finding out more about clinical trials. Book an appointment with our friendly team of specialist nurses today.

Please see the Footnotes for Healthcare Professionals at the bottom of this page to learn how this registry is compiled and why it was developed. 

ER+ or HR+ & HER2-

For patients who are oestrogen receptor positive, hormone receptor positive and HER2 (human epidermal growth factor receptor 2) negative.

A Study of SGN-B7H4V in Advanced Solid Tumors

Phase 1, advanced solid tumor: ER+ or HR+ & HER2- or TNBC

More info: clinicaltrials.gov/ct2/show/NCT05194072

Recruiting now in:

  • London

Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP

Phase 2, Patients with HR-positive, HER negative tumors or triple negative tumors

More info: clinicaltrials.gov/ct2/show/NCT04796324

Recruiting now in:

  • Edinburgh
  • Gillingham
  • Glasgow
  • Leeds
  • Swansea
  • Taunton

ASCENT-07: Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/​Human Epidermal Growth Factor Receptor 2 Negative (HR+/​HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Phase 3 trial for HR+ HER2- metastatic breast cancer patients who have had disease progression after endocrine therapy and are candidates for first line chemotherapy in the metastatic setting

More info: clinicaltrials.gov/study/NCT05840211

Recruiting now in:

  • London
  • Manchester
  • Nottingham
  • Sutton

CAPItello-292: Capivasertib + CDK4/​6i + Fulvestrant for Advanced/​Metastatic HR+/​HER2- Breast Cancer (CAPItello-292)

Phase 1b/3 trial for metastatic HR+/HER2- breast cancer. Patients must be eligible for fulvestrant therapy and at least one of the following: palbociclib, ribociclib, or abemaciclib, as per local investigator assessment.

More info: www.clinicaltrials.gov/study/NCT04862663

Recruiting now in:

  • London
  • Londonderry (NI)
  • Taunton
  • York

CONCEPT: Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer

Phase 2, ER+ or HR+ & HER2- or ER- & HER2- (TNBC)

More info: www.clinicaltrials.gov/study/NCT03048942

Recruiting now in:

  • Bath
  • Blackburn
  • Bristol
  • Cardiff
  • Exeter
  • London
  • Newcastle
  • Nottingham
  • Plymouth
  • Taunton
  • Truro
  • Worcester

CYCAD-1: A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

First In Human, Phase I/IIa trial for ER+ HER2- advanced breast cancer patients

More info: classic.clinicaltrials.gov/ct2/show/NCT06188520

Recruiting now in:

  • Cambridge
  • London

D4 Choline Breast PET/CT: Investigation of Changes in Tumour Choline Metabolism in Estrogen-receptor Positive / HER2 Negative Breast Cancer Patients Treated With CDK4/6 Inhibitors and Endocrine Therapy

Observational imaging study

More info: clinicaltrials.gov/ct2/show/NCT04276272

Recruiting now in:

  • London

ELECTRA: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer

Phase 1b/2: Patients with brain metastases that are ER+ or HR+ & HER2- who have had at least one endocrine therapy, up to two chemotherapy regimens and up to two prior CDK 4/6 inhibitors, not including abemaciclib

More info: www.clinicaltrials.gov/study/NCT05386108

Recruiting now in:

  • Liverpool
  • London
  • Manchester

ELUCIDATE: Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors

Phase 1 & 2, advanced solid tumor study. Patients must be HR+ and HER2- and have experienced disease progression with prior treatment that included a CD4/CDK6 inhibitor

More info: www.clinicaltrials.gov/study/NCT05985655

Recruiting now in:

  • Glasgow
  • London
  • Manchester
  • Newcastle
  • Oxford

evERA Breast Cancer: A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Metastatic Breast Can

Phase 3, prior endocrine therapy in combination with cyclin-dependent kinase 4/6 inhibitors.

More info: clinicaltrials.gov/ct2/show/NCT05306340

Recruiting now in:

  • Dorset
  • London
  • Manchester
  • Nottingham

FAIM: Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

Phase 2, HR+/HER2- metastatic breast cancer & previously treated with no more than one prior line of chemotherapy for advanced disease

More info: clinicaltrials.gov/study/NCT04920708

Recruiting now in:

  • Cambridge
  • Edinburgh
  • Glasgow
  • London
  • Manchester
  • Nottingham
  • Truro

INAVO121: A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/​6i and En

Phase 3: Patients who are ER+ or HR+ & HER2- and have a PIK3CA mutation and have progressed during or after CDK4/6 Inhibitor and Endocrine Combination Therapy

More info: www.clinicaltrials.gov/study/NCT05646862

Recruiting now in:

  • Basingstoke
  • Blackpool
  • Dumfries
  • Edinburgh
  • Livingston
  • London
  • Maidstone
  • Northwood
  • Oxford
  • Preston
  • Winchester

JEWEL-101: Study of XB002 in Subjects With Solid Tumors

Phase 1, Metastatic Solid Tumors - metastatic breast cancer patients must be TNBC or ER+/HR+ & HER2-

More info: clinicaltrials.gov/study/NCT04925284

Recruiting now in:

  • Cardiff
  • Glasgow
  • Leicester
  • London
  • Newcastle

KORTUC Phase II: Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer

Phase 2, Breast metastases should be well controlled or oligometastatic & radical/high dose palliative radiotherapy required for lifetime control of local morbidities

More info: clinicaltrials.gov/ct2/show/NCT03946202

Recruiting now in:

  • Cambridge
  • Glasgow
  • Manchester
  • Stoke-on-trent
  • Sutton
  • Truro

Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Expanded Access for ER+ HER2- metastatic breast cancer

More info: clinicaltrials.gov/ct2/show/NCT03763604

Recruiting now in:

  • Cambridge
  • Newcastle
  • Radlett

Phase 1/​2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/​HER2-/​ER+ Breast Cancer

Phase 1/​2, Metastatic Androgen Receptor Positive (AR+)/​HER2-/​ER+ Breast Cancer, where no conventional therapy is available

More info: www.clinicaltrials.gov/study/NCT05573126

Recruiting now in:

  • Liverpool
  • London
  • Manchester

SERENA-6: Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression

Phase 3, ER+ & HER2- & ESR1m+

More info: clinicaltrials.gov/ct2/show/NCT04964934

Recruiting now in:

  • Blackpool
  • Cambridge
  • London
  • Manchester
  • Nottingham
  • Portsmouth
  • Sheffield
  • Sutton
  • Taunton

Study of INCB123667 in Subjects With Advanced Solid Tumors

advanced solid tumor HR+ & HER2- or TNBC

More info: clinicaltrials.gov/ct2/show/NCT05238922

Recruiting now in:

  • London
  • Newcastle

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i)

Phase 1, either: HR+ & HER2- or HR+ & HER2+

More info: clinicaltrials.gov/ct2/show/NCT04557449

Recruiting now in:

  • Edinburgh
  • London
  • Manchester

SUMIT-ELA: A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/​HER2-negative Breast Cancer

Phase 1b/2: Recieved prior AI in combination with a CDK4/6i as the last therapy

More info: clinicaltrials.gov/study/NCT05963997

Recruiting now in:

  • Belfast
  • Manchester
  • Oxford

VELA: Study of BLU-222 in Advanced Solid Tumors

Phase 1/2 trial for advanced solid tumors including metastatic HR+ HER2- breast cancer that has progressed following CDK4/6 inhibitor treatment

More info: www.clinicaltrials.gov/study/NCT05252416

Recruiting now in:

  • London

HER2+

For patients who are HER2 (human epidermal growth factor receptor 2) positive.

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

Phase 1, HER2+ advanced solid tumors that have no authorized or effective therapy available, or for patients for whom such therapies are considered inappropriate by the Investigator.

More info: www.clinicaltrials.gov/study/NCT05873686

Recruiting now in:

  • Edinburgh
  • Sutton

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Phase 3 trial for PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer. Patients will be excluded if they have any prior systemic non-hormonal anti-cancer therapy for locally advanced or metastatic HER2-positive breast cancer prior to initiation of induc

More info: www.clinicaltrials.gov/study/NCT05894239

Recruiting now in:

  • Blackpool
  • Nottingham
  • Oxford

A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

Phase 1, HER2+ solid tumour, cohort 1 is open to different types of advanced cancer, other cohorts are specific to lung cancer

More info: www.clinicaltrials.gov/study/NCT04886804

Recruiting now in:

  • London
  • Sutton

DB RESPOND: An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/​or Metastatic Breast Cancer

Observational Study of Patients Initiating Trastuzumab Deruxtecan for First or Second Treatment Line for HER2+ Metastatic Breast Cancer

More info: clinicaltrials.gov/study/NCT05592483

Recruiting now in:

  • Coventry
  • Huddersfield
  • Inverness
  • Keighley
  • Leeds
  • Londonderry (NI)
  • Manchester

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Phase 1, Cohort 1: HER2+ Cohort 2: HER2-low

More info: clinicaltrials.gov/ct2/show/NCT04042701

Recruiting now in:

  • London
  • Manchester
  • Sutton

HER2CLIMB-05: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Phase 3, HER2+

More info: clinicaltrials.gov/ct2/show/NCT05132582

Recruiting now in:

  • Edinburgh
  • London
  • Manchester
  • Sutton

heredERA Breast Cancer: A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer

Phase 3, HR+ & HER2+

More info: clinicaltrials.gov/ct2/show/NCT05296798

Recruiting now in:

  • Bangor
  • Bath
  • Blackpool
  • Cornwall
  • London
  • Maidstone
  • Nottingham
  • Preston
  • Rhyl
  • Stockton-on-Tees
  • Swansea

KORTUC Phase II: Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer

Phase 2, Breast metastases should be well controlled or oligometastatic & radical/high dose palliative radiotherapy required for lifetime control of local morbidities

More info: clinicaltrials.gov/ct2/show/NCT03946202

Recruiting now in:

  • Cambridge
  • Glasgow
  • Manchester
  • Stoke-on-trent
  • Sutton
  • Truro

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i)

Phase 1, either: HR+ & HER2- or HR+ & HER2+

More info: clinicaltrials.gov/ct2/show/NCT04557449

Recruiting now in:

  • Edinburgh
  • London
  • Manchester

HER2-

For patients who are HER2 (human epidermal growth factor receptor 2) negative.

A Study of SGN-B6A in Advanced Solid Tumors

Phase 1, advanced solid tumor HER2-

More info: clinicaltrials.gov/ct2/show/NCT04389632

Recruiting now in:

  • London
  • Sutton

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Phase 1 & 2, advanced solid tumor: HER2- & BRCA mutation OR TNBC with no BRCA mutation

More info: clinicaltrials.gov/ct2/show/NCT02264678

Recruiting now in:

  • Bristol
  • Cambridge
  • Coventry
  • London
  • Manchester
  • Oxford
  • Sutton
  • Withington

CERTIS1: Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

advanced solid tumor HER2- & mutation in one of: BRCA, PALB2, RAD51C, or RAD51D

More info: clinicaltrials.gov/ct2/show/NCT05417594

Recruiting now in:

  • Glasgow
  • Newcastle

KORTUC Phase II: Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer

Phase 2, Breast metastases should be well controlled or oligometastatic & radical/high dose palliative radiotherapy required for lifetime control of local morbidities

More info: clinicaltrials.gov/ct2/show/NCT03946202

Recruiting now in:

  • Cambridge
  • Glasgow
  • Manchester
  • Stoke-on-trent
  • Sutton
  • Truro

TNBC

For patients who have Triple Negative Breast Cancer (TNBC) and are therefore oestrogen receptor negative, hormone receptor negative and HER2 (human epidermal growth factor receptor 2) negative.

A Study of NX-1607 in Adults With Advanced Malignancies

Phase 1, advanced solid tumor TNBC

More info: clinicaltrials.gov/ct2/show/NCT05107674

Recruiting now in:

  • Cambridge
  • Glasgow
  • London
  • Manchester
  • Newcastle
  • Oxford
  • Sutton

A Study of SGN-B7H4V in Advanced Solid Tumors

Phase 1, advanced solid tumor: ER+ or HR+ & HER2- or TNBC

More info: clinicaltrials.gov/ct2/show/NCT05194072

Recruiting now in:

  • London

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

advanced solid tumor TNBC

More info: clinicaltrials.gov/ct2/show/NCT04300556

Recruiting now in:

  • London
  • Manchester

Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP

Phase 2, Patients with HR-positive, HER negative tumors or triple negative tumors

More info: clinicaltrials.gov/ct2/show/NCT04796324

Recruiting now in:

  • Edinburgh
  • Gillingham
  • Glasgow
  • Leeds
  • Swansea
  • Taunton

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Phase 1 & 2, advanced solid tumor: HER2- & BRCA mutation OR TNBC with no BRCA mutation

More info: clinicaltrials.gov/ct2/show/NCT02264678

Recruiting now in:

  • Bristol
  • Cambridge
  • Coventry
  • London
  • Manchester
  • Oxford
  • Sutton
  • Withington

ASCENT-03: Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer

Phase 3, metastatic untreated TNBC

More info: clinicaltrials.gov/ct2/show/NCT05382299

Recruiting now in:

  • Cheltenham
  • Glasgow
  • Leeds
  • London

ASCENT-04: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Phase 3, TNBC & tumors express programmed cell death ligand 1 (PD-L1).

More info: clinicaltrials.gov/ct2/show/NCT05382286

Recruiting now in:

  • Edinburgh
  • Glasgow
  • Leeds
  • London
  • Nottingham

ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab

Phase 1, advanced solid tumor TNBC

More info: clinicaltrials.gov/ct2/show/NCT05082259

Recruiting now in:

  • Sutton

CONCEPT: Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer

Phase 2, ER+ or HR+ & HER2- or ER- & HER2- (TNBC)

More info: www.clinicaltrials.gov/study/NCT03048942

Recruiting now in:

  • Bath
  • Blackburn
  • Bristol
  • Cardiff
  • Exeter
  • London
  • Newcastle
  • Nottingham
  • Plymouth
  • Taunton
  • Truro
  • Worcester

CURATE: TT-702 in Patients With Advanced Solid Tumours

Phase 1 & 2, advanced solid tumor TNBC

More info: clinicaltrials.gov/ct2/show/NCT05272709

Recruiting now in:

  • London
  • Manchester
  • Southampton

FORTITUDE-301: A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Phase 1, advanced solid tumor TNBC & FGFR2b Overexpression

More info: clinicaltrials.gov/ct2/show/NCT05325866

Recruiting now in:

  • Manchester
  • Sheffield

HMBD-001 in Advanced HER3 Positive Solid Tumours

Phase 1 & 2, advanced solid HER3+ tumours, including TNBC

More info: clinicaltrials.gov/ct2/show/NCT05057013

Recruiting now in:

  • London
  • Oxford

JEWEL-101: Study of XB002 in Subjects With Solid Tumors

Phase 1, Metastatic Solid Tumors - metastatic breast cancer patients must be TNBC or ER+/HR+ & HER2-

More info: clinicaltrials.gov/study/NCT04925284

Recruiting now in:

  • Cardiff
  • Glasgow
  • Leicester
  • London
  • Newcastle

KORTUC Phase II: Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer

Phase 2, Breast metastases should be well controlled or oligometastatic & radical/high dose palliative radiotherapy required for lifetime control of local morbidities

More info: clinicaltrials.gov/ct2/show/NCT03946202

Recruiting now in:

  • Cambridge
  • Glasgow
  • Manchester
  • Stoke-on-trent
  • Sutton
  • Truro

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Phase Ib/II, TNBC

More info: www.clinicaltrials.gov/study/NCT05714553

Recruiting now in:

  • Birmingham
  • London
  • Manchester

PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

Phase 1, AR+ TNBC

More info: clinicaltrials.gov/ct2/show/NCT04360941

Recruiting now in:

  • London
  • Manchester
  • Nottingham
  • Sheffield

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Phase 1 & 2, advanced solid tumor TNBC

More info: clinicaltrials.gov/ct2/show/NCT04180371

Recruiting now in:

  • Cambridge
  • Leeds
  • London
  • Manchester
  • Newcastle

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumors Malignancies

Phase 1 & 2, advanced solid tumor TNBC & Nectin-4 expression

More info: clinicaltrials.gov/ct2/show/NCT04561362

Recruiting now in:

  • London
  • Manchester

Study of INCB123667 in Subjects With Advanced Solid Tumors

advanced solid tumor HR+ & HER2- or TNBC

More info: clinicaltrials.gov/ct2/show/NCT05238922

Recruiting now in:

  • London
  • Newcastle

The first-in-human trial of MDX-124 in patients with advanced cancer

Phase 1 First in Human, TNBC and solid tumour must overexpress ANXA1

More info: www.isrctn.com/ISRCTN78740398

Recruiting now in:

  • Edinburgh
  • Liverpool
  • Oxford

TROPION-Breast02: A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy

Phase 3, TNBC & not a candidate for PD-1/PD-L1 inhibitor therapy

More info: clinicaltrials.gov/ct2/show/NCT05374512

Recruiting now in:

  • Bristol
  • Cardiff
  • Edinburgh
  • London
  • Newcastle
  • Northampton
  • Nottingham
  • Swansea
  • Warwick

TROPION-Breast05: A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic TNBC

Phase 3, PD-L1 positive TNBC

More info: www.clinicaltrials.gov/study/NCT06103864

Recruiting now in:

  • Cardiff
  • Leicester
  • Liverpool
  • London
  • Sutton

Solid Tumour Studies

Studies which typically investigate many solid, late stage (i.e., advanced) cancer types within one research study, including secondary breast cancer.

A first in human study to investigate the safety and tolerability of CV6-168 in combination with anti-cancer treatments in patients with advanced cancer

Phase 1/2a, advanced solid tumor study. First in human study in which patients of many different metastatic cancer types will be recruited. Patients must have failed at least one standard therapy.

More info: www.isrctn.com/ISRCTN12434145

Recruiting now in:

  • Belfast
  • Glasgow
  • Newcastle
  • Sutton

A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521

Phase 1, solid tumors of any origin

More info: clinicaltrials.gov/ct2/show/NCT05323045

Recruiting now in:

  • London

A modular, multi-part, multi-arm, open-label, phase I/II study to evaluate the safety and tolerability of GRWD5769 alone and in combination with anticancer treatments in patients with solid malignancies

Phase 1 advanced solid tumor study. Patients must have advanced or metastatic solid tumors that are not considered appropriate for further standard treatment or confirmed progressive disease after having received at least 12 weeks of prior anti-PD-1 or an

More info: www.isrctn.com/ISRCTN45104480

Recruiting now in:

  • Edinburgh
  • London
  • Manchester

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

Phase 1, Part A of study is dose escalation for advanced solid tumors

More info: clinicaltrials.gov/study/NCT05226507

Recruiting now in:

  • Cambridge
  • Glasgow
  • Sutton

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

Phase 1, HER2+ advanced solid tumors that have no authorized or effective therapy available, or for patients for whom such therapies are considered inappropriate by the Investigator.

More info: www.clinicaltrials.gov/study/NCT05873686

Recruiting now in:

  • Edinburgh
  • Sutton

A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma

Phase 1 & 2, advanced solid tumor

More info: clinicaltrials.gov/ct2/show/NCT03829254

Recruiting now in:

  • Edinburgh
  • Glasgow
  • Manchester
  • Newcastle
  • Oxford

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

Phase 1, advanced solid tumor

More info: clinicaltrials.gov/ct2/show/NCT04969835

Recruiting now in:

  • Glasgow
  • Leeds
  • London
  • Manchester
  • Newcastle

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Phase 1 advanced solid tumor study. Patients must have advanced or metastatic solid tumors that are not considered appropriate for further standard treatment

More info: www.clinicaltrials.gov/study/NCT04657068

Recruiting now in:

  • Glasgow
  • London

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Phase 1, advanced solid tumor

More info: clinicaltrials.gov/study/NCT03526835

Recruiting now in:

  • London

A Study of SGN-PDL1V in Advanced Solid Tumors

Phase 1, advanced solid tumor

More info: clinicaltrials.gov/ct2/show/NCT05208762

Recruiting now in:

  • London
  • Sutton

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Phase 1, advanced solid tumor with a KRAS G12C mutation.

More info: clinicaltrials.gov/study/NCT04449874

Recruiting now in:

  • Birmingham
  • Cardiff
  • London
  • Manchester

A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

Phase 1, HER2+ solid tumour, cohort 1 is open to different types of advanced cancer, other cohorts are specific to lung cancer

More info: www.clinicaltrials.gov/study/NCT04886804

Recruiting now in:

  • London
  • Sutton

ANV419-001: A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients With Advanced Cancer

Phase 1 First in Human trial for advanced solid tumors in which no further available standard therapy likely to confer clinical benefit

More info: www.clinicaltrials.gov/study/NCT04855929

Recruiting now in:

  • Sutton

Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumours

Phase 1, advanced solid tumor

More info: clinicaltrials.gov/ct2/show/NCT03767075

Recruiting now in:

  • Cambridge

DDRiver Solid Tumors 301: M1774 in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors

Phase 1 First in Human: Metastatic disease that is refractory to standard therapy

More info: www.clinicaltrials.gov/study/NCT04170153

Recruiting now in:

  • Cambridge
  • Manchester
  • Newcastle
  • Sutton

DETERMINE: Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial

Phase 2 & 3, "umbrella-basket platform trial" including common cancers with rare actionable genomic alterations

More info: www.clinicaltrials.gov/study/NCT05722886

Recruiting now in:

  • Belfast
  • Birmingham
  • Bristol
  • Cambridge
  • Cardiff
  • Edinburgh
  • Glasgow
  • Leicester
  • Liverpool
  • London
  • Manchester
  • Newcastle
  • Oxford

ELUCIDATE: Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors

Phase 1 & 2, advanced solid tumor study. Patients must be HR+ and HER2- and have experienced disease progression with prior treatment that included a CD4/CDK6 inhibitor

More info: www.clinicaltrials.gov/study/NCT05985655

Recruiting now in:

  • Glasgow
  • London
  • Manchester
  • Newcastle
  • Oxford

EVICTION: First-in-Human Study of ICT01 in Patients With Advanced Cancer

Phase 1 & 2, relapsed patients not responding to standard treatment who have advanced-stage or recurrent cancer

More info: www.clinicaltrials.gov/study/NCT04243499

Recruiting now in:

  • London

First in Human Study of T3P-Y058-739 (T3P)

Phase 1, advanced solid tumor

More info: clinicaltrials.gov/ct2/show/NCT05120596

Recruiting now in:

  • Glasgow
  • Leeds
  • London

First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies

Phase 1/2a, advanced solid tumour

More info: www.clinicaltrials.gov/study/NCT05123482

Recruiting now in:

  • Cambridge
  • Cardiff
  • London

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Phase 1: advanced solid tumors where curative treatment options have been exhausted

More info: www.clinicaltrials.gov/study/NCT05277051

Recruiting now in:

  • Manchester
  • Sutton

GEN1047 for Solid Tumors - First in Human (FIH) Trial

First In Human, Phase I/IIa trial for advanced solid tumors for which there is no further available standard therapy likely to confer clinical benefit

More info: clinicaltrials.gov/study/NCT05180474

Recruiting now in:

  • London
  • Manchester

HMBD-001 in Advanced HER3 Positive Solid Tumours

Phase 1 & 2, advanced solid HER3+ tumours, including TNBC

More info: clinicaltrials.gov/ct2/show/NCT05057013

Recruiting now in:

  • London
  • Oxford

Integrated short-term palliative rehabilitation in incurable cancer

incurable solid tumour, recruitment is irrespective of timing in relation to any oncology or palliative care treatments

More info: www.isrctn.com/ISRCTN16705336

Recruiting now in:

  • London

JEWEL-101: Study of XB002 in Subjects With Solid Tumors

Phase 1, Metastatic Solid Tumors - metastatic breast cancer patients must be TNBC or ER+/HR+ & HER2-

More info: clinicaltrials.gov/study/NCT04925284

Recruiting now in:

  • Cardiff
  • Glasgow
  • Leicester
  • London
  • Newcastle

LIBRETTO-001: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Phase 1, advanced solid tumor & RET Fusion Positive

More info: clinicaltrials.gov/ct2/show/NCT03157128

Recruiting now in:

  • Sutton

MITOPE: Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Patients with malignant pleural effusion from any solid tumor, including secondary cancers

More info: www.clinicaltrials.gov/study/NCT05278975

Recruiting now in:

  • Bristol
  • Glasgow
  • Leeds
  • Leicester
  • London
  • Newcastle
  • Oxford
  • Sutton

MK-7339-002 /​ LYNK-002: Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer

Phase 1 study for multiple types of advanced/metastatic cancer. For metastatic breast cancer, patients can't have a germline BRCA mutation.

More info: clinicaltrials.gov/study/NCT03742895

Recruiting now in:

  • Newcastle

New Formulation Study of Inupadenant (EOS100850) in Patients With Cancer

Phase 1, advanced solid tumor

More info: clinicaltrials.gov/ct2/show/NCT05117177

Recruiting now in:

  • Sutton

PETRA: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Phase 1 & 2, advanced solid tumor

More info: clinicaltrials.gov/ct2/show/NCT04644068

Recruiting now in:

  • Cambridge
  • Manchester
  • Oxford
  • Sutton

Phase I Trial of VS-6766 Alone and in Combination With Everolimus (RAF/MEK)

Phase 1, advanced solid tumor

More info: clinicaltrials.gov/ct2/show/study/NCT02407509

Recruiting now in:

  • London
  • Sutton

Phase Ia, First in Human Open Label Dose Escalation Trial Evaluating Intravenous BI 1703880 in Combination With Intravenous Ezabenlimab for Treatment of Advanced Solid Tumours

Phase 1, advanced solid tumor

More info: clinicaltrials.gov/ct2/show/NCT05471856

Recruiting now in:

  • London
  • Oxford
  • Sutton

PIKASSO-01: A Study of LOXO-783 in Patients With Breast Cancer/​Other Solid Tumors

Phase 1 trial for patients with advanced breast cancer or other solid tumors. Patients must have a PIK3CA mutation and have had 2-5 prior regimens for advanced disease treatment.

More info: clinicaltrials.gov/study/NCT05307705

Recruiting now in:

  • London
  • Sutton

POTENTIA: Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours

Phase 1, advanced solid tumor that is PSMA+

More info: clinicaltrials.gov/ct2/show/NCT04839991

Recruiting now in:

  • London
  • Manchester
  • Sutton

PYNNACLE: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Phase 1/2 study, for patients who have advanced solid metastatic tumors that have a TP53 Y220C mutation

More info: www.clinicaltrials.gov/study/NCT04585750

Recruiting now in:

  • London

SABR-COMET-3: Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer

Phase 3, patients must have 1-3 current metastases and a maximum 8 lifetime metastases

More info: www.clinicaltrials.gov/study/NCT03862911

Recruiting now in:

  • Aberdeen
  • Edinburgh
  • Glasgow

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Phase 1, advanced solid tumor: PRAME positive tumor

More info: clinicaltrials.gov/ct2/show/NCT04262466

Recruiting now in:

  • Glasgow
  • Liverpool
  • London
  • Manchester
  • Oxford
  • Sutton

Safety and Preliminary Efficacy of BNT314 With or Without an Immune Checkpoint Inhibitor in Cancer Patients With Malignant Solid Tumors

Phase 1 & 2, advanced solid tumor study. For patients whom at the discretion of the investigator there is no available standard therapy likely to confer clinical benefit.

More info: www.clinicaltrials.gov/study/NCT06150183

Recruiting now in:

  • Sutton

Study of GS-4528 in Adults With Solid Tumors

Phase 1, advanced solid tumor study. Patients have received, been intolerant to, or have been ineligible for all treatment known to confer clinical benefit

More info: clinicaltrials.gov/study/NCT05840224

Recruiting now in:

  • London
  • Sutton

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

Phase 1, advanced solid tumor

More info: clinicaltrials.gov/ct2/show/NCT04336241

Recruiting now in:

  • Liverpool
  • London
  • Oxford
  • Sutton

Study to Evaluate CCS1477 in Advanced Tumours

Phase 1 & 2, advanced solid tumor

More info: clinicaltrials.gov/ct2/show/NCT03568656

Recruiting now in:

  • Belfast
  • Birmingham
  • Cambridge
  • Edinburgh
  • Glasgow
  • Leicester
  • Manchester
  • Newcastle
  • Southampton
  • Sutton

TARGET National: Tumour Characterisation to Guide Experimental Targeted Therapy

Prospective, to determine the number of patients matched to a trial of an experimental therapeutic agent based on molecular findings from ctDNA or tumour

More info: clinicaltrials.gov/ct2/show/NCT04723316

Recruiting now in:

  • Belfast
  • Birmingham
  • Cambridge
  • Cardiff
  • Edinburgh
  • Glasgow
  • Leeds
  • Leicester
  • London
  • Manchester
  • Newcastle
  • Oxford
  • Preston
  • Sheffield
  • Southampton
  • Wirral

The first-in-human trial of MDX-124 in patients with advanced cancer

Phase 1 First in Human, TNBC and solid tumour must overexpress ANXA1

More info: www.isrctn.com/ISRCTN78740398

Recruiting now in:

  • Edinburgh
  • Liverpool
  • Oxford

TIG-006: Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

Phase 1, advanced solid tumors with no further standard treatment available

More info: www.clinicaltrials.gov/study/NCT05060432

Recruiting now in:

  • London

TRIDENT-1: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 advanced solid tumors that have an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement

More info: clinicaltrials.gov/study/NCT03093116

Recruiting now in:

  • London
  • Manchester
  • Sutton

VELA: Study of BLU-222 in Advanced Solid Tumors

Phase 1/2 trial for advanced solid tumors including metastatic HR+ HER2- breast cancer that has progressed following CDK4/6 inhibitor treatment

More info: www.clinicaltrials.gov/study/NCT05252416

Recruiting now in:

  • London

Footnotes for Healthcare Professionals

 The registry was last updated on: 2nd June 2024.  

How the registry is complied

The databases used to compile this clinical trial registry are: clinicaltrials.gov, NIHR Be Part of Research and Cancer Research UK.

Only secondary breast cancer clinical trials that are noted as actively recruiting in the UK on ClinicalTrials.gov are listed in this registry. However, there can be a delay in how quickly ClinicalTrials.gov is updated and a study might be listed as actively recruiting, but has already closed to recruitment.    

There is a possibility that other clinical trials might be available due to the speed at which ClinicalTrials.gov is updated by research teams.  

Next steps

You can find out more about each specific trial by clicking its associated study link. Our Patient Trials Advocate (PTA) service is available to conduct a bespoke and detailed clinical trials search. We support patients based in the UK however we can access information on international clinical trials. Patients can self-refer to the service here.

Send feedback on the registry to: clinical.trials@make2ndscount.co.uk

Development of the registry

Make 2nds Count created the registry based on the research findings of a national survey conducted in 2021 that was funded by Make 2nds Count. The study found that secondary breast cancer patients had a lack of information about clinical trials, limited opportunities to discuss trials with their clinical team and many advocated for a patient friendly clinical trial registry specific to secondary breast cancer.

As a charity, Make 2nds Count pioneered the innovative Patient Trials Advocate (PTA) service and this dedicated UK Clinical Trials Registry to address the informational needs raised in the survey, but there is more work to be done. We all share a responsibility in igniting a national conversation about clinical trials.